The products of somatostatin in the circulation have been investigated by high-pressure liquid chromatography. Plasma collected 1 min after intravenous injection of cyclic (oxidized) somatostatin showed a single ultraviolet absorbing peak. The 
INTRODUCTION
It has been established by many workers that somatostatin is widely distributed throughout the body and has multiple inhibitory actions, among them inhibition of the secretion of growth hormone, insulin, glucagon and gastrin (Bloom, Mortimer, Thorner, Besser, Hall, Gomez-Pan, Roy, Russell, Coy, Kastin «fe Schally, 1974; Vale, Brazeau, Rivier, Brown, Boss, Rivier, Burgus, Ling & Guillemin, 1975) . Somatostatin might, therefore, have future clinical applications in diabetes mellitus, possibly in combination with insulin (Gerich, 1976) , or in the treatment of gastric acid hypersécrétion (Lippmann & Borella, 1976) . Although the short-lived effects of somatostatin are a limitation on its clinical usefulness, very little information is available as to its fate in vivo. Until it is understood how and where the molecule is taken up and degraded, no guidance can be offered as to which analogues should be synthesized in the search for longer acting and more potent substances, In this study, synthetic linear and cyclic somatostatin (structures shown in Table 1) were injected intravenously into rats, and high-pressure liquid chromatography (HPLC) was used for the detection and identification of the peptides and their fragments in the blood.
MATERIALS AND METHODS

Materials
Disposable syringes used for extraction columns were from Gillette Surgical (Isleworth, Middlesex). Porous Teflon disks were cut from sheets obtained from Aerox Plastics (Stroud, Gloucestershire). Spherisorb ODS-silica (10 µ ) was obtained from Phase Separations (Queensferry, Clwyd) (Ellman, 1959) 1976; Krummen & Frei, 1977 for the rat (Hobbs, 1967) (Table 3 ) showed an extremely rapid conversion to the des-Ala1 form, particularly in whole blood; the reaction was slowed down, but not totally inhibited, by EDTA. Cyclic somatostatin (200 µg) was incubated in 6 ml plasma or 12 ml whole blood, extracted and then purified by high-pressure liquid chromatography. The experiment was repeated with the addition of 110 µ EDTA. The alanine content relative to phenylalanine was used to determine the percentage of [des-Ala1]-somatostatin present.
One minute after an i.v. injection of 1 mg linear somatostatin, no peptides containing -SH groups could be detected in plasma, compared with a control plasma extract ( Fig.  2a and b) . In addition, no u.v. absorbing products were present indicating that less than 2% of the injected somatostatin remained in the circulation at this time. A number of experiments were carried out in vitro in which linear somatostatin was incubated in plasma at 37°C , and portions of plasma were removed, extracted and chromatographed at various time intervals. As shown in Fig. 3 , over a period of 3 min the u.v. absorbance of the somato¬ statin peak remained constant. However, the amount of -SH-containing peptide rapidly decreased, falling to less than 1% by 3 min. It was concluded that the linear peptides had been oxidized to the closed-ring form which eluted from the column in the same place as somatostatin. A control sample incubated in Krebs-Ringer bicarbonate buffer containing calcium ions remained fully reduced. Incubation time (s) Fig. 3 (Vale et al. 1975 (Vale et al. 1975; Garsky, Clark & Grant, 1976) suggesting that the cyclic structure is necessary for biological activity.
It has been demonstrated that somatostatin and somatostatin-like peptides are present in appreciable quantities in the extrahypothalamic brain, stomach and pancreas (Arimura, Sato, Dupont, Nishi «fe Schally, 1975; Dubois, 1975; Hökfelt, Hellerström, Efendic, Johansson, Luft & Arimura, 1975 ). Thus it is quite possible that in some instances soma¬ tostatin could be acting as a local hormone, and as such it would have to be rapidly inacti¬ vated upon release to prevent it from being returned to the blood and affecting other target tissues.
The clearance of linear somatostatin (more than 98% in 1 min) is surprisingly efficient, even compared with that of cyclic somatostatin. Therefore, the question of whether soma¬ tostatin is released from its storage cells in the reduced or oxidized form is of considerable interest. Although somatostatin has been isolated in the cyclized form, cyclization could have occurred during isolation and purification. Most cells contain glutathione with the redox potential lying strongly in favour of the reduced state and it is therefore quite possible that inside the cell, somatostatin is in the linear (reduced) form. If this were so, upon its release any peptide reaching its target receptors might undergo ring closure whilst the remainder would be rapidly removed from the circulation. In this way the requirement for rapid inactivation of a locally acting hormone could be satisfied.
The experimental results have shown that clearance of the linear form must occur before appreciable cyclization can take place, since the cyclic form, once produced, will leave the circulation more slowly. The disappearance of the linear form seems to be too rapid to be accounted for in terms of peptide actually leaving the capillary beds. Perhaps the presence of free -SH groups leads to direct binding to the capillary walls.
In conclusion, investigation of products in the blood has shown that linear and cyclic somatostatin are rapidly cleared from the circulation. Only one fragment was detected and this was [des-Ala1]-somatostatin, which is probably fully biologically active. It appears that inactivation of somatostatin must occur after it has entered the tissues and a full understanding of the behaviour of this peptide will require further investigation of its fate once it has left the circulation.
